Compare Organon & Co. Common Stock (OGN) vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $19.76 (market cap $7.97B). The key difference: Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is far larger — about 2.2× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF for 56 Days on average.
| OGN | PDBC | |
|---|---|---|
Market Cap | $3.61B | $7.97B |
Volume | 1,808,049 | 3,246,731 |
Sector | Health | — |
52-Week High | $13.81 | $20.10 |
52-Week Low | $5.70 | $13.19 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $11.03B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
PDBC, an ETF tracking diversified commodities, trades at $19.98, up 0.6% today, with a bullish technical signal from moving averages. The fund has delivered strong performance, rising 45.66% year-to-date through Q3 2026, driven by energy and agricultural gains amid geopolitical tensions. Short interest surged 215.4% in September 2026, indicating increased bearish speculation, while institutional investments from firms like Arlington Capital and Advisortrust Partners show confidence.
The outlook remains positive due to robust commodity trends, but risks include heightened short interest and geopolitical volatility. Investors benefit from broad commodity exposure without K-1 tax complexity, though price swings from supply shocks or economic shifts pose challenges. The fund's momentum and defensive appeal in uncertain markets support a favorable view, but monitoring short-term pressure is essential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →
